Similarly, in another previous study, we also described the interaction between MSI and epigenetic alteration (methylation) in these CRC patients, which suggested an opportunity for potential use of certain immune checkpoint inhibitors (CTLA4 and HAVCR2 inhibitors) in CRC with MSI [70]. Here, CTLA4 is linked to colorectal carcinoma.